Candel Therapeutics Files Q1 2025 10-Q
Ticker: CADL · Form: 10-Q · Filed: May 13, 2025 · CIK: 1841387
Sentiment: neutral
Topics: 10-Q, biotech, financing, acquisition
TL;DR
CADL Q1 10-Q filed. ATM offering active, Periphagen acquisition details in. Check financials.
AI Summary
Candel Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its activities, including its At-The-Market Offering from January 1, 2025, to March 31, 2025. Key agreements and acquisitions mentioned include the Brigham and Women's Hospital, Inc. License Agreement and the Periphagen Inc. Asset Acquisition.
Why It Matters
This filing provides investors with an update on Candel Therapeutics' financial position and operational activities for the first quarter of 2025, including details on ongoing financing and strategic acquisitions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Candel Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2025-01-01 to 2025-03-31 — At-The-Market Offering Period (Specifies the timeframe during which the company may have issued stock.)
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 117 Kendrick Street, Suite 450, Needham, MA 02494 (address) — Company's business and mailing address
- Brigham and Women's Hospital, Inc. (company) — Party to a license agreement
- Periphagen Inc. (company) — Subject of an asset acquisition
- 2025-01-01 (date) — Start date of At-The-Market Offering
- 2025-03-31 (date) — End date of At-The-Market Offering and Periphagen Inc. Asset Acquisition
FAQ
What is the primary business of Candel Therapeutics, Inc.?
Candel Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
What is the fiscal year end for Candel Therapeutics, Inc.?
The fiscal year end for Candel Therapeutics, Inc. is December 31st.
When was the Brigham and Women's Hospital, Inc. License Agreement entered into?
The Brigham and Women's Hospital, Inc. License Agreement was entered into on January 20, 2018.
What is the context of the Periphagen Inc. Asset Acquisition?
The Periphagen Inc. Asset Acquisition is noted with dates of December 9, 2019, and March 31, 2025, suggesting a transaction or reporting related to it.
What type of loan agreement is mentioned in relation to Candel Therapeutics?
A Term Loan Agreement is mentioned, with specific dates of February 24, 2022, and associated maximum amounts.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Candel Therapeutics, Inc. (CADL).